Navigation Links
Aesthera Announces ANVISA Clearance to Market Photopneumatic Platforms in Brazil

Breakthrough Isolaz Pro to Launch into High Growth Brazilian Market for Aesthetic and Medical Procedures

PLEASANTON, Calif., May 20 /PRNewswire/ -- Aesthera announced today the receipt of ANVISA clearance to market their proprietary Isolaz Pro photopneumatic(TM) based platforms in Brazil. ANVISA (Agencia Nacional de Vigilancia Sanitaria) is a Brazilian national health surveillance and regulatory agency charged with clearing all applications to market medical devices in Brazil.

Aesthera also announced its partner in the region, Sao Paulo based LBT Lasers, a leading distributor of advanced aesthetic technology solutions for physician practices. Aesthera's Isolaz Pro and other soon to be launched technologies will be exclusively represented by LBT sales professionals in the Brazilian market.

"This is the most recent milestone in our aggressive build-out of Aesthera's international distribution channel. We look forward to partnering with LBT Lasers as we introduce the Isolaz Pro(TM) to Brazilian physicians," said Alon Maor, president and CEO of Aesthera Corp. Aesthera's Isolaz platform is the only FDA cleared device for the treatment of comedonal and pustular acne, in addition to being cleared for the skin rejuvenation and hair removal. "LBT Lasers has a longstanding reputation as a premier provider of innovative aesthetic technology. Their strong network coupled with large customer base of over 300 physician offices will accelerate the rapid adoption of Photopneumatic platforms to over 5000 dermatologists in the Brazilian marketplace," he adds.

"The Isolaz Pro platform will offer Brazilian physicians a much needed treatment solution for acne as well as Profusion - a breakthrough skin therapy to enhance skin treatment outcomes for acne, body tightening, skin rejuvenation and skin lightening," says Alexandre Ferraz, CEO, LBT Laser. "We are proud that Aesthera has selected LBT Lasers as their exclusive distributor in our region. The addition of Aesthera's products to our offering demonstrates our commitment to bringing only the most innovative and effective technologies to our Brazilian customers. The Brazilian market for aesthetics is strongly positioned for continued robust growth in the coming years," he adds.

Aesthera's Isolaz platform will be launched to the Brazilian market at key academic meetings starting with the Teraderm - Sociedade Brasileira de Dermatologia meeting (May 22 - 23, 2009), the Congresso Brasileiro de Medicina Estetica (June 3 - 6, 2009) and the upcoming Congresso Brasileiro de Cirurgia Dermatologica between June 10 - 14, 2009.

About Photopneumatic(TM) Technology

Photopneumatic Therapy, that powers the Isolaz(TM) and Isolaz Pro(TM) system, is a proprietary combination of pneumatic energy and broad band light. Photopneumatic devices are the only laser or light based devices cleared for the treatment of inflammatory acne, comedonal acne and pustular acne. They are also cleared for the treatment of mild to moderate inflammatory acne. Photopneumatic treatments have an immediate visible impact on acne 24 - 48 hour post first treatment and are painless. Facial treatments take approximately 10 minutes, require no anesthetics or numbing creams and provide additional cosmetic benefits such as smoother appearing skin. Additionally, Photopneumatic Therapy is also cleared for the treatment of benign vascular and pigmented lesions and hair removal.

About Aesthera Corporation

Aesthera ( develops, manufactures and markets light-based aesthetic treatment systems - the Isolaz(TM) and Isolaz Pro(TM) platforms - based on proprietary Photopneumatic(TM) technology.

    Sarvar Kothavala
    Aesthera Corp.

SOURCE Aesthera Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results
Post Your Comments:
(Date:11/26/2015)... 2015 ... Research Laboratories, a leading independent and ... has formed a strategic partnership with ... Health for joint work on clinical ... ) , --> ,     ...
(Date:11/25/2015)... Studies reveal the differences in ... pave the way for more effective treatment for one of ...   --> --> Gum ... in cats, yet relatively little was understood about the bacteria ... been conducted by researchers from the WALTHAM Centre for Pet ...
(Date:11/25/2015)... , Nov. 25, 2015 Orexigen® Therapeutics, ... will participate in a fireside chat discussion at the ... New York . The discussion is scheduled for ... .  A replay will be available ... Contact:McDavid Stilwell  , Julie NormartVP, Corporate Communications and ...
(Date:11/24/2015)... Nov. 24, 2015 Cepheid (NASDAQ: CPHD ... at the following conference, and invited investors to participate ...      Tuesday, December 1, 2015 at 11.00 a.m. ...      Tuesday, December 1, 2015 at 11.00 a.m. ... New York, NY      Tuesday, December ...
Breaking Biology Technology:
(Date:11/17/2015)... -- Vigilant Solutions announces today that Mr. Dick W. ... --> --> Mr. Boyce ... at TPG Capital, one of the largest global investment ... revenue.  He founded and led TPG,s Operating Group, which ... 1997 to 2013.  In his first role, he served ...
(Date:11/12/2015)... 2015  A golden retriever that stayed healthy despite ... has provided a new lead for treating this muscle-wasting ... Institute of MIT and Harvard and the University of ... Cell, pinpoints a protective gene that ... effects. The Boston Children,s lab of Lou Kunkel ...
(Date:11/11/2015)... , Nov. 11, 2015   MedNet Solutions , an ... of clinical research, is pleased to announce that it will ... Trials (PCT) event, to be held November 17-19 in ... to view live demonstrations of iMedNet , ... how iMedNet has been able to deliver time ...
Breaking Biology News(10 mins):